Published in Healthcare Mergers, Acquisitions and Ventures Week, May 15th, 2004
Atypical BioVentures is a newly formed venture capital fund affiliated with Aurora Capital, LLC, an investment bank specializing in biotechnology and other life science companies.
Richard Salvador, president and CEO of AngioGenex and Bill Garland, chief operating officer, expressed their pleasure that Atypical BioVentures made its first investment in AngioGenex. "We appreciate the validation of our technology and the vote of confidence in our management team that this investment represents."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.